JMPWA
KERX

JP Morgan Private Wealth Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32,637
Closed -$111K – 1650
2018
Q3 		$111K Buy
32,637
+2,109
+7% +$7.6K ﹤0.01% 1524
2018
Q2 		$115K Buy
30,528
+5,908
+24% +$28.8K ﹤0.01% 1412
2018
Q1 		$100K Buy
24,620
+433
+2% +$2.02K ﹤0.01% 1220
2017
Q4 		$113K Sell
24,187
-466
-2% -$2.57K ﹤0.01% 1225
2017
Q3 		$175K Buy
24,653
+2,821
+13% +$20.3K ﹤0.01% 1169
2017
Q2 		$158K Buy
21,832
+5,252
+32% +$32.8K ﹤0.01% 1169
2017
Q1 		$102K Buy
+16,580
New +$90.8K ﹤0.01% 1290

JP Morgan Private Wealth Advisors's KERX Position: Q4 2018 in Review

JP Morgan Private Wealth Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 32,637 shares — an estimated $111K sold.

JP Morgan Private Wealth Advisors first reported a position in KERX in Q1 2017 and held it in 7 quarters. The position peaked at $175K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • JP Morgan Private Wealth Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 32,637 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $111K.
  • JP Morgan Private Wealth Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
  • JP Morgan Private Wealth Advisors's Keryx Biopharmaceuticals Inc position peaked at $175K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.